Editors' picks from other sources

Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

New and experimental hepatitis C treatment news

Show

From To
New and experimental hepatitis C treatment
Abbott Announces Phase 3 Interferon-free Hepatitis C Regimens to be Studied in Broad Patient Populations

The phase 3 clinical trials are designed to evaluate safety and efficacy of a 12-week regimen of three direct acting antivirals (DAA), with and without ribavirin, for the treatment of HCV in genotype 1 (GT1) non-cirrhotic, treatment-naïve and treatment-experienced patients. An additional phase 3 trial will study triple-DAAs, with ribavirin, in patients with cirrhosis for 12 or 24 weeks.

Published
14 November 2012
From
Abbott press release
New and experimental hepatitis C treatment
Hep C Competitors Cede Space To Gilead And Bristol-Myers And Turn To Niche Uses

The analyst community might have already written the epitaph for Vertex Pharmaceuticals’ (VRTX) Incivek and Merck & Co’s (MRK) Victrelis, but the search for growth for the two hepatitis C treatments continues apace. The AASLD Liver Meeting became an opportunity for the two companies to showcase potential new uses in hard-to-treat populations.

Published
13 November 2012
From
Seeking Alpha
New and experimental hepatitis C treatment
Gilead, Abbott Unwrap Dueling Hep C Pill Data

Hepatitis C researchers, with investors tagging along, are gathering in Boston at the Liver Meeting, the annual conference sponsored by the American Association for the Study of Liver Disease. The most important data presentations over the next four days will focus on the race to develop new pills, which when used in various combinations, can replace the traditional injections long required to treat and cure hepatitis C.

Published
12 November 2012
From
The Street
New and experimental hepatitis C treatment
ALS-2200 (VX-135), Vertex's Oral Nucleotide Analogue in Development for Hepatitis C

Vertex Pharmaceuticals Incorporated today announced that data on ALS-2200 (VX-135), an oral medicine Vertex is developing for the treatment of hepatitis C, are being presented for the first time at The Liver Meeting®, the 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD).

Published
11 November 2012
From
Vertex press release
New and experimental hepatitis C treatment
Twice-Daily Telaprevir Achieved Viral Cure (SVR12) Rates Similar to Those Treated Three Times Daily

Vertex Pharmaceuticals Incorporated (NAS: VRTX) today announced that new data from a Phase 3 study in people being treated for hepatitis C for the first time showed similar rates of viral cure (SVR12, HCV RNA levels < 25 IU/mL 12 weeks after the end of all treatment) when telaprevir was given twice daily compared to three times daily, the currently approved dosing schedule.

Published
11 November 2012
From
Vertex press release
New and experimental hepatitis C treatment
Boehringer Ingelheim to start late-stage hepatitis C drug trial

Boehringer Ingelheim said on Saturday it plans to initiate a late-stage clinical trial of its experimental hepatitis C treatment following promising results from earlier studies.

Published
11 November 2012
From
Reuters
New and experimental hepatitis C treatment
Idenix Reports On IDX719 and IDX184

Idenix Pharmaceuticals, Inc. (Nasdaq:IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced the presentation of safety and antiviral activity results for the Company's clinical-stage hepatitis C virus (HCV) drug candidates - IDX719, a next-generation pan-genotypic NS5A inhibitor, and IDX184, a nucleotide polymerase inhibitor.

Published
11 November 2012
From
Idenix press release
New and experimental hepatitis C treatment
Merck will initiate interferon-free Phase II clinical trials for MK-5172, an investigational, once-daily, oral treatment for chronic hepatitis C virus

Merck has announced plans to initiate two new clinical trials with MK-5172, its investigational, once-daily, oral HCV NS3/4A protease inhibitor for the treatment of chronic hepatitis C (HCV) infection.

Published
06 November 2012
From
Merck press release
New and experimental hepatitis C treatment
Avoiding Missteps When Evaluating New HCV Trial Data

For the last 20 years, I have evaluated treatments for chronic hepatitis C by studying results from randomized, controlled clinical trials. I hunt for the “intent-to-treat” (ITT) sustained virologic response (SVR) rates and use these to compare the different regimens.

Published
05 November 2012
From
Clinical Care Options (requires registration)
Pharmaceutical industry
Gilead and the Pharmasset Deal: Do the Ends Justify the Means?

David Sopek analyses how the hepatitis C market needs to develop - and how pharmaceutical companies may seek to influence testing policy - in order to justify Gilead's $11 billion purchase of Pharmasset.

Published
05 November 2012
From
PropThink
← Prev1...23456...22Next →

Filter by country